MULTIPLE BRANCH PEPTIDE CONSTRUCTIONS

Abstract: Multiple branch peptide constructions formed from peptides derived from the envelope transmembrane glycoprotein gp41 of HIV, and including the consensus sequence RQGY preceded by 0 to 4 amino acid residues and succeeded by 2 to 4 amino acid residues, most preferably RQGYSPL, show increased receptor affinity and prevent cell-to-cell fusion. They have a direct virostatic effect. Because they present the same peptide sequence several times, these MBPCs are able to neutralize in vitro the different steps of virus envelope/cell membrane fusion, and infected cell membrane/uninfected cell membrane fusion of several strains of HIV-1 and HIV-2. These results open a potential use in treatment of HIV infection.

Description: TITLE Multiple Branch Peptide Constructions DESCRIPTION The invention relates to multiple branch peptide constructions (MBPCs) and to their use in the treatment of Human Immunodeficiency Virus (HIV) infections. The use of radially branched systems in polymers has been known for a long time in classical polymer chemistry. This system has been used by J. P. Tarn [Proc. Natl. Acad. Sci. USA 85, 5409-5413 (1988)] to develop antigens without the use of ambiguous carriers, using lysine skeletons. Those antigens were designed to generate vaccines against a variety of diseases. Antigens for generating vaccines against HIN infection are described by Tarn in WO93/03766. He called them Multiple Antigenic Peptide Systems (MAPS), consistent with their conceived use. The present inventors, along with others, found that similar constructions with shorter peptides derived from the N3 loop of the surface envelope glycoprotein gpl20 of HIN offered a direct therapeutic approach to the treatment of HIN infections, as described in WO95/07929. The name MAPS was then inappropriate, and the compounds were renamed as MBPCs. The MBPCs of WO95/07929 interfered with the virus envelope - cell membrane fusion step and also the infected cell membrane - uninfected cell membrane fusion step, either step being thought to be indispensable for cell infection, virus multiplication and the spread of virus in the host organism, by blockading the CD4 receptor present in cells such as lymphocytes and macrophages, apparently by attaching to a membrane co-receptor which is distinct from the CD4 binding receptor, without causing the cell to lose its ability to be activated by other antigens or mitogens. The inventors have now discovered further MBPCs which are effective as treatments for HIN infections. These use peptides derived from the HIV envelope transmembrane glycoprotein gp41. The amino acid sequences of these MBPCs were selected on the basis of sequence homologies between various HIV isolates. The choice of gp41 amongst viral proteins was based on the following: i) the importance of this domain in the virus-cell and cell-cell fusion processes leading to virus entry into the host cell, ii) the importance of the gpl60 splicing into gpl20 and gp41 for the fusogenic activity to take place. iii) the existence of neutralizing anti-gp41 antibodies, e.g. antibody 2F5, and iv) the existence of a unique disulphide bridge, in contrast to gpl20, which makes it easier to obtain peptides mimicking specific conformational domains of gp41. It is presumed that the gp41 -derived MBPCs of this invention interfere with a critical step of the fusion process. The invention provides a multiple branch peptide construction and a method for the therapeutic treatment of patients with HIV infections. The multiple branch peptide construction comprises a core matrix to which are bonded from 2 to 16, and preferably from 4 to 16 peptides, each of which comprises the sequence RQGY preceded by from 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. Preferably, the peptides bonded to an 8 or 16-branched core matrix are RQGYSPL. The method for the therapeutic treatment of patients with HIV infections comprises administering such an MBPC to the patient, preferably in such an amount as to induce in the patient a blood concentration of the MBPC of from 10 "7 to 10 "4 molar. The core matrix is a dendritic polymer which is branched in nature, preferably with each of the branches thereof being identical. The core matrix is based on a core molecule which has at least two functional groups to which molecular branches having terminal functional groups are covalently bonded. Suitable core molecules include ammonia or ethylenediamine. Suitable molecular branches include acrylic ester monomers which are polymerized onto the core molecule. Such molecules may be created to present varying number of branches, depending on the number of monomers branched from the core molecule. The preferred core molecule is lysine. A central lysine residue is bonded to two lysine residues, each through its carboxyl group, to one of the amino groups of the central lysine residue. This provides a molecule with four amino groups, which may be the core matrix for an MBPC having four peptides. Alternatively, one can provide a molecule with eight branches by bonding four lysine residues through their carboxyl groups to one of the amino groups of the lysine residues which are attached to the central lysine. This molecule can serve as the core matrix for an MBPC having eight peptides or can alternatively receive eight lysine residues to form a core matrix for an MBPC having sixteen peptides. The C-ends of peptides are covalently bonded to each of the branches of the core matrix to form the MBPC. The peptides may be the same, which is preferred, or may be different from one another. The resulting molecule has a cluster of peptides at the surface and an interior core matrix which is not presented and is therefore not antigenic. Spacers may, if desired, be included between the peptides and the core matrix. The carboxyl group of ie first lysine residue may be left free, amidated, or coupled to β-alanine or another blocking compound. Peptides can include D or L-amino acid residues. D amino acids last longer in vivo because they are harder for peptidase to cut, but the L amino acids have better activity, as discussed below. Moreover, peptide analogues, synthetic constructs using the carbon skeleton of peptides but omitting the -CONH- peptide bonds, can be employed in place of peptides. Thus, it should be understood that references to peptides herein may also be taken to include peptide analogues. It is believed that peptide analogues will be more resistant to peptidase and last longer in vivo. If the peptide is too long, the MBPC will become antigenic. It is therefore desirable that each peptide should have not more than ten, and preferably not more than nine, amino acid residues. The preferred MBPCs for use in this invention are RL. l: (RQGYSPL) 8 -(K) 4 -(K) 2 -K-βA-OH and RL.2: (RQGYSPL) 16 -(K) 8 -(K) 4 -(K) 2 -K-β A-OH The OH terminal shown above on the β-alanine indicates the carboxyl group thereof, with the amino group being attached to the carboxyl group of the lysine residue. The carboxyl group of the β-alanine may alternatively be modified to form a carboxamide terminal. The preparation of the MBPCs of the invention, having a branched core with peptides attached thereto, can be effected by methods known in the art, see e.g. Tarn et al, J. Immun. 148, 914-920 (1992). Preferably, for small quantities (under one kilogram), a solid phase method is used to obtain the MBPCs. Stepwise assembly of the peptide chains can be carried out automatically on 4-(oxymethyl)-phenylacetamidomethyl copoly(styrene-l % divinyl benzene). The Boc/benzyl strategy may be used, including a systematic double coupling scheme with hydroxybenzotriazole active esters (Boc-amino-acid-OBt). The final cleaving from resin is effected with strong acid, such as anhydrous hydrogen fluoride (1 hour at 0°C). The MBPC is then washed with diethyl ether and solubilized in water. After lyophilization, the MBPC may be pre-purified on a P2 or G15 type molecular filtration column, equilibrated with O. IN acetic acid. The eluate fraction may then be recovered. The purification step is achieved by using C 8 or C 18 reversed-phase HPLC. The MBPC may be characterized by its amino acid content after acid hydrolysis (6N HCl, 115°C, 24 hours) and electrospray mass spectrometry. The gp41-derived MBPCs of the invention have been tested in vitro for their ability to inhibit HIV-induced syncytium formation, and infection of human lymphocytes by both HIV-1 and HIV-2 viruses (several laboratory strains including LAV-2/B, an HIV-2 virus able to infect some CD47GalCer " cells, as well as clinical isolates such as JRCSF, P16/B6 and P16/C9). The diverse peptide constructions were found to be inactive, except for MBPC RL1 which possessed potent antiviral properties in all tests. By contrast, the monomeric RQGYSPL was found to be inactive. Some results are shown in Tables 1 and 2 below. Similar results were obtained with other HIV strains and clinical isolates tested so far. The MBPC RL1 showed neither cellular toxicity nor lethal activity when injected by the intracerebroventricular route in both C57/BL6 and Balb-C mice (concentration tested was 3 x 10 "3 M, corresponding to 100 μg of peptide injected per 20g mouse. TABLE 1 Inhibition of the HxlO (HIV-1) strain infectivity by the MBPCs RLl and SPC3 Peptides Molarity OD p24 (ng/ml) Inhibition (%) SPC3-D4 5 x 10 "5 0.052 0.05556143 98.89 1 x 10 '5 0.211 0.48654334 89.13 5 x 10 "6 0.849 2.21589212 50.78 1 x 10 "6 1.797 4.78552009 0 SPC3-D5 5 x 10- 5 0.066 0.09350952 98.47 RL1-D4 5 x 10 "5 0.047 0.04200854 99.09 1 x 10- 5 0.359 0.88770888 79.82 5 x 10 "6 0.657 1.69546114 61.45 1 x 10 "6 1.148 3.02635495 31.29 RL1-D5 5 x 10 "5 0.035 0.00948160 99.75 SPC3 is (GPGRAF) 8 -(K) 4 -(K) 2 -K-βA-OH as disclosed in WO95/07929. D4 and D5 refer to days 4 and 5 of the experiment. OD stands for Optical Density. N.B. Experiments were performed with non diluted virus solution. TABLE 2 Inhibition (%) of clinical isolates infectivity by the MBPCs RLl and SPC3. [cone] 1 x 10 "5 5 x 10 "6 1 x 10 "6 5 x 10 '7 1 x 10 "7 5 x 10 "8 SPC3 85.7 50.0 28.6 0 0 0 RLl 89.3 70.0 67.1 40.8 18.3 0 Example shown is the HIV-1 W5A2A9 isolate. N.B. Experiments were performed with non diluted virus solution.

Claims: CLAIMS 1. A multiple branch peptide construction comprising a core matrix to which are bonded from 2 to 16 peptides, each of which comprises the amino acid sequence RQGY preceded by 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. 2. A peptide construction according to claim 1 in which there are from 4 to 16 peptides bonded to the core matrix. 3. A peptide construction according to claim 1 or claim 2 in which each peptide is the same. 4. A peptide construction according to claim 1 or claim 2 in which each peptide is RQGYSPL. 5. A peptide construction according to claim 4 in which there are 8 or 16 peptides RQGYSPL. 6. A peptide construction according to any of claims 1 to 3 in which each peptide includes not more than 10 amino acid residues. 7. A peptide construction according to any of claims 1 to 3 in which each peptide includes not more than 9 amino acid residues. 9. A peptide construction according to any preceding claim in which the core matrix is comprised of lysine residues. 10. A peptide construction according to any preceding claim in which there are spacers between the core matrix and the peptides. 11. A peptide construction according to claim 1 in which the peptides are peptide analogues. 12. A peptide construction according to claim 1 in which the peptides include at least one D-amino acid residue. 13. A peptide construction according to any preceding claim which is non-i munogenic at a blood concentration of up to 10 "4 molar. 14. A medicament comprising a multiple branch peptide construction according to any preceding claim in admixture with a pharmaceutically acceptable diluent or carrier. 15. Use of a multiple branch peptide construction according to any of claim 1 to 13 for the preparation of a medicament for the treatment of HIV infections. 16. A method of treating HIV infections comprising administering to a patient a multiple branch peptide construction according to any of claims 1 to 13. 17. A method according to claim 16 in which the multiple branch peptide construction is administered to the patient in an amount sufficient to induce in the patient a blood concentration of less than 10 "4 molar. 18. A method according to claim 16 or claim 17 in which the multiple branch peptide construction is administered to the patient in an amount sufficient to induce in the patient a blood concentration of more than 10 "7 molar. 19. A method of treating HIV infections comprising administering to a patient a medicament according to claim 14. 20. A method according to claim 19 in which the medicament is administered to the patient in an amount sufficient to induce in the patient a blood concentration of the multiple branch peptide construction of less than 10 "7 molar. 21. A method according to claim 19 in which the medicament is administered to the patient in an amount sufficient to induce in the patient a blood concentration of the multiple branch peptide construction of more than 10 "4 molar. 22. A method for the preparation of a multiple branch peptide construction comprising a core matrix to which are bonded from 2 to 16 peptides, each of which comprises the amino acid sequence RQGY preceded by 0 to 4 amino acid residues and succeeded by 2 to 4 amino acid residues, the method comprising solid phase stepwise elongation of the peptide chains on a resin, followed by cleavage of the multiple branch peptide construction from the resin. 23. A method according to claim 22 in which the resin is 4-oxymethyl-phenylacetamidomethyl copoly(styrene-l % divinylbenzene). 24. A method according to claim 22 or claim 23 in which the Boc/benzyl strategy is used, including systematic double coupling with hydroxybenzotriazole active esters (Boc-amino-acid-OBt) . 25. A method according to any of claims 16 to 18 in which the cleavage from the resin is effected with anhydrous hydrogen fluoride at 0°C.

Inventors: MABROUK KAMEL, ROCHAT HERVE, SABATIER JEAN-MARC, VAN RIETSCHOTEN JURPHAAS, MABROUK, KAMEL, ROCHAT, HERVE, SABATIER, JEAN-MARC, VAN RIETSCHOTEN, JURPHAAS
Applicants: ARMEL SA, MABROUK KAMEL, RIETSCHOTEN JURPHAAS VAN, ROCHAT HERVE, SABATIER JEAN MARC, ARMEL S.A., MABROUK, KAMEL, ROCHAT, HERVE, SABATIER, JEAN-MARC, VAN RIETSCHOTEN, JURPHAAS
Application year: 1997
Main classification: C07K14
IPC codes: A61K38, C07K14